TY - JOUR AU - Slamon, D. J. AU - Clark, G. M. AU - Wong, S. G. AU - Levin, W. J. AU - Ullrich, A. AU - McGuire, W. L. PY - 1987 DA - 1987// TI - Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene JO - Science VL - 235 UR - https://doi.org/10.1126/science.3798106 DO - 10.1126/science.3798106 ID - Slamon1987 ER - TY - JOUR AU - Slamon, D. J. AU - Godolphin, W. AU - Jones, L. A. AU - Holt, J. A. AU - Wong, S. G. AU - Keith, D. E. AU - Levin, W. J. AU - Stuart, S. G. AU - Udove, J. AU - Ullrich, A. PY - 1989 DA - 1989// TI - Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer JO - Science VL - 244 UR - https://doi.org/10.1126/science.2470152 DO - 10.1126/science.2470152 ID - Slamon1989 ER - TY - JOUR AU - Press, M. F. AU - Bernstein, L. AU - Thomas, P. A. AU - Meisner, L. F. AU - Zhou, J. Y. AU - Ma, Y. AU - Hung, G. AU - Robinson, R. A. AU - Harris, C. AU - El-Naggar, A. PY - 1997 DA - 1997// TI - HER-2/neu gene amplification characterized by fluorescence in situhybridization: poor prognosis in node-negative breast carcinomas JO - J Clin Oncol VL - 15 ID - Press1997 ER - TY - JOUR AU - Carter, P. AU - Presta, L. AU - Gorman, C. M. AU - Ridgway, J. B. AU - Henner, D. AU - Wong, W. L. AU - Rowland, A. M. AU - Kotts, C. AU - Carver, M. E. AU - Shepard, H. M. PY - 1992 DA - 1992// TI - Humanization of an anti-p185her2 antibody for human cancer therapy JO - Proc Natl Acad Sci USA VL - 89 UR - https://doi.org/10.1073/pnas.89.10.4285 DO - 10.1073/pnas.89.10.4285 ID - Carter1992 ER - TY - JOUR AU - Romond, E. H. AU - Perez, E. A. AU - Bryant, J. AU - Suman, V. J. AU - Geyer, C. E. AU - Davidson, N. E. AU - Tan-Chiu, E. AU - Martino, S. AU - Paik, S. AU - Kaufman, P. A. PY - 2005 DA - 2005// TI - Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer JO - N Engl J Med VL - 353 UR - https://doi.org/10.1056/NEJMoa052122 DO - 10.1056/NEJMoa052122 ID - Romond2005 ER - TY - JOUR AU - Piccart-Gebhart, M. J. AU - Procter, M. AU - Leyland-Jones, B. AU - Goldhirsch, A. AU - Untch, M. AU - Smith, I. AU - Gianni, L. AU - Baselga, J. AU - Bell, R. AU - Jackisch, C. PY - 2005 DA - 2005// TI - Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer JO - N Engl J Med VL - 353 UR - https://doi.org/10.1056/NEJMoa052306 DO - 10.1056/NEJMoa052306 ID - Piccart-Gebhart2005 ER - TY - JOUR AU - Buzdar, A. U. AU - Ibrahim, N. K. AU - Francis, D. AU - Booser, D. J. AU - Thomas, E. S. AU - Theriault, R. L. AU - Pusztai, L. AU - Green, M. C. AU - Arun, B. K. AU - Giordano, S. H. PY - 2005 DA - 2005// TI - Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.07.032 DO - 10.1200/JCO.2005.07.032 ID - Buzdar2005 ER - TY - JOUR AU - Nahta, R. AU - Esteva, F. J. PY - 2006 DA - 2006// TI - Herceptin: mechanisms of action and resistance JO - Cancer Lett VL - 232 UR - https://doi.org/10.1016/j.canlet.2005.01.041 DO - 10.1016/j.canlet.2005.01.041 ID - Nahta2006 ER - TY - JOUR AU - Baselga, J. AU - Albanell, J. AU - Molina, M. A. AU - Arribas, J. PY - 2001 DA - 2001// TI - Mechanism of action of trastuzumab and scientific update JO - Semin Oncol VL - 28 UR - https://doi.org/10.1016/S0093-7754(01)90276-3 DO - 10.1016/S0093-7754(01)90276-3 ID - Baselga2001 ER - TY - JOUR AU - Sliwkowski, M. X. AU - Lofgren, J. A. AU - Lewis, G. D. AU - Hotaling, T. E. AU - Fendly, B. M. AU - Fox, J. A. PY - 1999 DA - 1999// TI - Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) JO - Semin Oncol VL - 26 ID - Sliwkowski1999 ER - TY - JOUR AU - Nagata, Y. AU - Lan, K. H. AU - Zhou, X. AU - Tan, M. AU - Esteva, F. J. AU - Sahin, A. A. AU - Klos, K. S. AU - Li, P. AU - Monia, B. P. AU - Nguyen, N. T. PY - 2004 DA - 2004// TI - PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients JO - Cancer Cell VL - 6 UR - https://doi.org/10.1016/j.ccr.2004.06.022 DO - 10.1016/j.ccr.2004.06.022 ID - Nagata2004 ER - TY - JOUR AU - Cooley, S. AU - Burns, L. J. AU - Repka, T. AU - Miller, J. S. PY - 1999 DA - 1999// TI - Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu JO - Exp Hematol VL - 27 UR - https://doi.org/10.1016/S0301-472X(99)00089-2 DO - 10.1016/S0301-472X(99)00089-2 ID - Cooley1999 ER - TY - JOUR AU - Clynes, R. A. AU - Towers, T. L. AU - Presta, L. G. AU - Ravetch, J. V. PY - 2000 DA - 2000// TI - Inhibitory Fc receptors modulate in vivocytoxicity against tumor targets JO - Nat Med VL - 6 UR - https://doi.org/10.1038/74704 DO - 10.1038/74704 ID - Clynes2000 ER - TY - JOUR AU - Gennari, R. AU - Menard, S. AU - Fagnoni, F. AU - Ponchio, L. AU - Scelsi, M. AU - Tagliabue, E. AU - Castiglioni, F. AU - Villani, L. AU - Magalotti, C. AU - Gibelli, N. PY - 2004 DA - 2004// TI - Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2 JO - Clin Cancer Res VL - 10 UR - https://doi.org/10.1158/1078-0432.CCR-04-0225 DO - 10.1158/1078-0432.CCR-04-0225 ID - Gennari2004 ER - TY - JOUR AU - Arnould, L. AU - Gelly, M. AU - Penault-Llorca, F. AU - Benoit, L. AU - Bonnetain, F. AU - Migeon, C. AU - Cabaret, V. AU - Fermeaux, V. AU - Bertheau, P. AU - Garnier, J. PY - 2006 DA - 2006// TI - Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? JO - Br J Cancer VL - 94 UR - https://doi.org/10.1038/sj.bjc.6602930 DO - 10.1038/sj.bjc.6602930 ID - Arnould2006 ER - TY - JOUR AU - Izumi, Y. AU - Xu, L. AU - di Tomaso, E. AU - Fukumura, D. AU - Jain, R. K. PY - 2002 DA - 2002// TI - Tumour biology: Herceptin acts as an anti-angiogenic cocktail JO - Nature VL - 416 UR - https://doi.org/10.1038/416279b DO - 10.1038/416279b ID - Izumi2002 ER - TY - JOUR AU - Klos, K. S. AU - Zhou, X. AU - Lee, S. AU - Zhang, L. AU - Yang, W. AU - Nagata, Y. AU - Yu, D. PY - 2003 DA - 2003// TI - Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone JO - Cancer VL - 98 UR - https://doi.org/10.1002/cncr.11656 DO - 10.1002/cncr.11656 ID - Klos2003 ER - TY - CHAP AU - Wen, X. F. AU - Yang, G. AU - Mao, W. AU - Thornton, A. AU - Liu, J. AU - Bast, R. C. AU - Le, X. F. PY - 2006 DA - 2006// TI - HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy BT - Oncogene ID - Wen2006 ER - TY - JOUR AU - Baselga, J. AU - Tripathy, D. AU - Mendelsohn, J. AU - Baughman, S. AU - Benz, C. C. AU - Dantis, L. AU - Sklarin, N. T. AU - Seidman, A. D. AU - Hudis, C. A. AU - Moore, J. PY - 1996 DA - 1996// TI - Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer JO - J Clin Oncol VL - 14 ID - Baselga1996 ER - TY - JOUR AU - Cobleigh, M. A. AU - Vogel, C. L. AU - Tripathy, D. AU - Robert, N. J. AU - Scholl, S. AU - Fehrenbacher, L. AU - Wolter, J. M. AU - Paton, V. AU - Shak, S. AU - Lieberman, G. PY - 1999 DA - 1999// TI - Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER-2 overexpressing metastatic breast cancer that has progresssed after chemotherapy for metastatic disease JO - J Clin Oncol VL - 17 ID - Cobleigh1999 ER - TY - JOUR AU - Vogel, C. L. AU - Cobleigh, M. A. AU - Tripathy, D. AU - Gutheil, J. C. AU - Harris, L. N. AU - Fehrenbacher, L. AU - Slamon, D. J. AU - Murphy, M. AU - Novotny, W. F. AU - Burchmore, M. PY - 2002 DA - 2002// TI - Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.20.3.719 DO - 10.1200/JCO.20.3.719 ID - Vogel2002 ER - TY - JOUR AU - Seidman, A. D. AU - Fornier, M. N. AU - Esteva, F. J. AU - Tan, L. AU - Kaptain, S. AU - Bach, A. AU - Panageas, K. S. AU - Arroyo, C. AU - Valero, V. AU - Currie, V. PY - 2001 DA - 2001// TI - Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification JO - J Clin Oncol VL - 19 ID - Seidman2001 ER - TY - JOUR AU - Slamon, D. J. AU - Leyland-Jones, B. AU - Shak, S. AU - Fuchs, H. AU - Paton, V. AU - Bajamonde, A. AU - Fleming, T. AU - Eiermann, W. AU - Wolter, J. AU - Pegram, M. PY - 2001 DA - 2001// TI - Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 JO - N Engl J Med VL - 344 UR - https://doi.org/10.1056/NEJM200103153441101 DO - 10.1056/NEJM200103153441101 ID - Slamon2001 ER - TY - JOUR AU - Esteva, F. J. AU - Valero, V. AU - Booser, D. AU - Guerra, L. T. AU - Murray, J. L. AU - Pusztai, L. AU - Cristofanilli, M. AU - Arun, B. AU - Esmaeli, B. AU - Fritsche, H. A. PY - 2002 DA - 2002// TI - Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer JO - J Clin Oncol VL - 20 UR - https://doi.org/10.1200/JCO.2002.07.058 DO - 10.1200/JCO.2002.07.058 ID - Esteva2002 ER - TY - JOUR AU - Nahta, R. AU - Yu, D. AU - Hung, M. C. AU - Hortobagyi, G. N. AU - Esteva, F. J. PY - 2006 DA - 2006// TI - Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer JO - Nat Clin Pract Oncol VL - 3 UR - https://doi.org/10.1038/ncponc0509 DO - 10.1038/ncponc0509 ID - Nahta2006 ER - TY - JOUR AU - Price-Schiavi, S. A. AU - Jepson, S. AU - Li, P. AU - Arango, M. AU - Rudland, P. S. AU - Yee, L. AU - Carraway, K. L. PY - 2002 DA - 2002// TI - Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance JO - Int J Cancer VL - 99 UR - https://doi.org/10.1002/ijc.10410 DO - 10.1002/ijc.10410 ID - Price-Schiavi2002 ER - TY - JOUR AU - Nagy, P. AU - Friedlander, E. AU - Tanner, M. AU - Kapanen, A. I. AU - Carraway, K. L. AU - Isola, J. AU - Jovin, T. M. PY - 2005 DA - 2005// TI - Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line JO - Cancer Res VL - 65 ID - Nagy2005 ER - TY - JOUR AU - Carraway, K. L. AU - Price-Schiavi, S. A. AU - Komatsu, M. AU - Jepson, S. AU - Perez, A. AU - Carraway, C. A. PY - 2001 DA - 2001// TI - Muc4/sialomucin complex in the mammary gland and breast cancer JO - J Mammary Gland Biol Neoplasia VL - 6 UR - https://doi.org/10.1023/A:1011327708973 DO - 10.1023/A:1011327708973 ID - Carraway2001 ER - TY - JOUR AU - Akiyama, T. AU - Matsuda, S. AU - Namba, Y. AU - Saito, T. AU - Toyoshima, K. AU - Yamamoto, T. PY - 1991 DA - 1991// TI - The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain JO - Mol Cell Biol VL - 11 UR - https://doi.org/10.1128/MCB.11.2.833 DO - 10.1128/MCB.11.2.833 ID - Akiyama1991 ER - TY - JOUR AU - Tanner, M. AU - Kapanen, A. I. AU - Junttila, T. AU - Raheem, O. AU - Grenman, S. AU - Elo, J. AU - Elenius, K. AU - Isola, J. PY - 2004 DA - 2004// TI - Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer JO - Mol Cancer Ther VL - 3 ID - Tanner2004 ER - TY - JOUR AU - Lu, Y. AU - Zi, X. AU - Zhao, Y. AU - Mascarenhas, D. AU - Pollak, M. PY - 2001 DA - 2001// TI - Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin) JO - J Natl Cancer Inst VL - 93 UR - https://doi.org/10.1093/jnci/93.24.1852 DO - 10.1093/jnci/93.24.1852 ID - Lu2001 ER - TY - JOUR AU - Nahta, R. AU - Yuan, L. X. AU - Zhang, B. AU - Kobayashi, R. AU - Esteva, F. J. PY - 2005 DA - 2005// TI - Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells JO - Cancer Res VL - 65 UR - https://doi.org/10.1158/0008-5472.CAN-04-3841 DO - 10.1158/0008-5472.CAN-04-3841 ID - Nahta2005 ER - TY - JOUR AU - Lu, Y. AU - Zi, X. AU - Pollak, M. PY - 2004 DA - 2004// TI - Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells JO - Int J Cancer VL - 108 UR - https://doi.org/10.1002/ijc.11445 DO - 10.1002/ijc.11445 ID - Lu2004 ER - TY - JOUR AU - Yakes, F. M. AU - Chinratanalab, W. AU - Ritter, C. A. AU - King, W. AU - Seelig, S. AU - Arteaga, C. L. PY - 2002 DA - 2002// TI - Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action JO - Cancer Res VL - 62 ID - Yakes2002 ER - TY - JOUR AU - Le, X. F. AU - Claret, F. X. AU - Lammayot, A. AU - Tian, L. AU - Deshpande, D. AU - LaPushin, R. AU - Tari, A. M. AU - Bast, R. C. PY - 2003 DA - 2003// TI - The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition JO - J Biol Chem VL - 278 UR - https://doi.org/10.1074/jbc.M300848200 DO - 10.1074/jbc.M300848200 ID - Le2003 ER - TY - JOUR AU - Nahta, R. AU - Takahashi, T. AU - Ueno, N. T. AU - Hung, M. C. AU - Esteva, F. J. PY - 2004 DA - 2004// TI - P27 (kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells JO - Cancer Res VL - 64 UR - https://doi.org/10.1158/0008-5472.CAN-03-3900 DO - 10.1158/0008-5472.CAN-03-3900 ID - Nahta2004 ER - TY - JOUR AU - Chan, C. T. AU - Metz, M. Z. AU - Kane, S. E. PY - 2005 DA - 2005// TI - Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors JO - Breast Cancer Res Treat VL - 91 UR - https://doi.org/10.1007/s10549-004-7715-1 DO - 10.1007/s10549-004-7715-1 ID - Chan2005 ER - TY - JOUR AU - Lin, Y. Z. AU - Clinton, G. M. PY - 1991 DA - 1991// TI - A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells JO - Oncogene VL - 6 ID - Lin1991 ER - TY - JOUR AU - Pupa, S. M. AU - Menard, S. AU - Morelli, D. AU - Pozzi, B. AU - De Palo, G. AU - Colnaghi, M. I. PY - 1993 DA - 1993// TI - The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage JO - Oncogene VL - 8 ID - Pupa1993 ER - TY - JOUR AU - Zabrecky, J. R. AU - Lam, T. AU - McKenzie, S. J. AU - Carney, W. PY - 1991 DA - 1991// TI - The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, sk-br-3 JO - J Biol Chem VL - 266 ID - Zabrecky1991 ER - TY - JOUR AU - Colomer, R. AU - Montero, S. AU - Lluch, A. AU - Ojeda, B. AU - Barnadas, A. AU - Casado, A. AU - Massuti, B. AU - Cortes-Funes, H. AU - Lloveras, B. PY - 2000 DA - 2000// TI - Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer JO - Clin Cancer Res VL - 6 ID - Colomer2000 ER - TY - JOUR AU - Leitzel, K. AU - Teramoto, Y. AU - Konrad, K. AU - Chinchilli, V. M. AU - Volas, G. AU - Grossberg, H. AU - Harvey, H. AU - Demers, L. AU - Lipton, A. PY - 1995 DA - 1995// TI - Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer JO - J Clin Oncol VL - 13 ID - Leitzel1995 ER - TY - JOUR AU - Yamauchi, H. AU - O'Neill, A. AU - Gelman, R. AU - Carney, W. AU - Tenney, D. Y. AU - Hosch, S. AU - Hayes, D. F. PY - 1997 DA - 1997// TI - Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein JO - J Clin Oncol VL - 15 ID - Yamauchi1997 ER - TY - JOUR AU - Hayes, D. F. AU - Yamauchi, H. AU - Broadwater, G. AU - Cirrincione, C. T. AU - Rodrigue, S. P. AU - Berry, D. A. AU - Younger, J. AU - Panasci, L. L. AU - Millard, F. AU - Duggan, D. B. PY - 2001 DA - 2001// TI - Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662 JO - Clin Cancer Res VL - 7 ID - Hayes2001 ER - TY - JOUR AU - Christianson, T. A. AU - Doherty, J. K. AU - Lin, Y. J. AU - Ramsey, E. E. AU - Holmes, R. AU - Keenan, E. J. AU - Clinton, G. M. PY - 1998 DA - 1998// TI - NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer JO - Cancer Res VL - 58 ID - Christianson1998 ER - TY - JOUR AU - Molina, M. A. AU - Saez, R. AU - Ramsey, E. E. AU - Garcia-Barchino, M. J. AU - Rojo, F. AU - Evans, A. J. AU - Albanell, J. AU - Keenan, E. J. AU - Lluch, A. AU - Garcia-Conde, J. PY - 2002 DA - 2002// TI - NH2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer JO - Clin Cancer Res VL - 8 ID - Molina2002 ER - TY - JOUR AU - Molina, M. A. AU - Codony-Servat, J. AU - Albanell, J. AU - Rojo, F. AU - Arribas, J. AU - Baselga, J. PY - 2001 DA - 2001// TI - Trastuzumab (Herceptin), a humanized anti-HER2 receptor monoclonal antibody, inhibits basal and activated HER2 ectodomain cleavage in breast cancer cells JO - Cancer Res VL - 61 ID - Molina2001 ER - TY - JOUR AU - Esteva, F. J. AU - Cheli, C. AU - Fritsche, H. A. AU - Fornier, M. AU - Slamon, D. J. AU - Thiel, R. P. AU - Luftner, D. AU - Ghani, F. PY - 2004 DA - 2004// TI - Clinical utility of circulating HER-2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients undergoing trastuzumab-based therapy JO - Breast Can Res Treat VL - 88 ID - Esteva2004 ER - TY - JOUR AU - Kostler, W. J. AU - Schwab, B. AU - Singer, C. F. AU - Neumann, R. AU - Rucklinger, E. AU - Brodowicz, T. AU - Tomek, S. AU - Niedermayr, M. AU - Hejna, M. AU - Steger, G. G. PY - 2004 DA - 2004// TI - Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer JO - Clin Cancer Res VL - 10 UR - https://doi.org/10.1158/1078-0432.CCR-0385-3 DO - 10.1158/1078-0432.CCR-0385-3 ID - Kostler2004 ER - TY - JOUR AU - Fornier, M. N. AU - Seidman, A. D. AU - Schwartz, M. K. AU - Ghani, F. AU - Thiel, R. AU - Norton, L. AU - Hudis, C. PY - 2005 DA - 2005// TI - Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situhybridization and with response rate JO - Ann Oncol VL - 16 UR - https://doi.org/10.1093/annonc/mdi059 DO - 10.1093/annonc/mdi059 ID - Fornier2005 ER - TY - JOUR AU - Ali, S. M. AU - Esteva, F. J. AU - Fornier, M. AU - Gligorov, J. AU - Harris, L. AU - Kostler, W. J. AU - Luftner, D. AU - Pichon, M. F. AU - Tse, C. AU - Lipton, A. PY - 2006 DA - 2006// TI - Serum HER-2/neu change predicts clinical outcome to trastuzumab-based therapy JO - J Clin Oncol VL - 24 ID - Ali2006 ER - TY - JOUR AU - Anido, J. AU - Scaltriti, M. AU - Bech Serra, J. J. AU - Santiago Josefat, B. AU - Todo, F. R. AU - Baselga, J. AU - Arribas, J. PY - 2006 DA - 2006// TI - Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation JO - EMBO J VL - 25 UR - https://doi.org/10.1038/sj.emboj.7601191 DO - 10.1038/sj.emboj.7601191 ID - Anido2006 ER - TY - JOUR AU - Agus, D. B. AU - Akita, R. W. AU - Fox, W. D. AU - Lewis, G. D. AU - Higgins, B. AU - Pisacane, P. I. AU - Lofgren, J. A. AU - Tindell, C. AU - Evans, D. P. AU - Maiese, K. PY - 2002 DA - 2002// TI - Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth JO - Cancer Cell VL - 2 UR - https://doi.org/10.1016/S1535-6108(02)00097-1 DO - 10.1016/S1535-6108(02)00097-1 ID - Agus2002 ER - TY - JOUR AU - Cho, H. S. AU - Mason, K. AU - Ramyar, K. X. AU - Stanley, A. M. AU - Gabelli, S. B. AU - Denney, D. W. AU - Leahy, D. J. PY - 2003 DA - 2003// TI - Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab JO - Nature VL - 421 UR - https://doi.org/10.1038/nature01392 DO - 10.1038/nature01392 ID - Cho2003 ER - TY - JOUR AU - Franklin, M. C. AU - Carey, K. D. AU - Vajdos, F. F. AU - Leahy, D. J. AU - de Vos, A. M. AU - Sliwkowski, M. X. PY - 2004 DA - 2004// TI - Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex JO - Cancer Cell VL - 5 UR - https://doi.org/10.1016/S1535-6108(04)00083-2 DO - 10.1016/S1535-6108(04)00083-2 ID - Franklin2004 ER - TY - JOUR AU - Nahta, R. AU - Hung, M. C. AU - Esteva, F. J. PY - 2004 DA - 2004// TI - The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells JO - Cancer Res VL - 64 UR - https://doi.org/10.1158/0008-5472.CAN-03-3856 DO - 10.1158/0008-5472.CAN-03-3856 ID - Nahta2004 ER - TY - JOUR AU - Wood, E. R. AU - Truesdale, A. T. AU - McDonald, O. B. AU - Yuan, D. AU - Hassell, A. AU - Dickerson, S. H. AU - Ellis, B. AU - Pennisi, C. AU - Horne, E. AU - Lackey, K. PY - 2004 DA - 2004// TI - A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells JO - Cancer Res VL - 64 UR - https://doi.org/10.1158/0008-5472.CAN-04-1168 DO - 10.1158/0008-5472.CAN-04-1168 ID - Wood2004 ER - TY - JOUR AU - Xia, W. AU - Mullin, R. J. AU - Keith, B. R. AU - Liu, L. H. AU - Ma, H. AU - Rusnak, D. W. AU - Owens, G. AU - Alligood, K. J. AU - Spector, N. L. PY - 2002 DA - 2002// TI - Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways JO - Oncogene VL - 21 UR - https://doi.org/10.1038/sj.onc.1205794 DO - 10.1038/sj.onc.1205794 ID - Xia2002 ER - TY - JOUR AU - Xia, W. AU - Gerard, C. M. AU - Liu, L. AU - Baudson, N. M. AU - Ory, T. L. AU - Spector, N. L. PY - 2005 DA - 2005// TI - Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells JO - Oncogene VL - 24 UR - https://doi.org/10.1038/sj.onc.1208774 DO - 10.1038/sj.onc.1208774 ID - Xia2005 ER - TY - JOUR AU - Xia, W. AU - Bacus, S. AU - Hegde, P. AU - Husain, I. AU - Strum, J. AU - Liu, L. AU - Paulazzo, G. AU - Lyass, L. AU - Trusk, P. AU - Hill, J. PY - 2006 DA - 2006// TI - A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer JO - Proc Natl Acad Sci USA VL - 103 UR - https://doi.org/10.1073/pnas.0602468103 DO - 10.1073/pnas.0602468103 ID - Xia2006 ER - TY - JOUR AU - Konecny, G. E. AU - Pegram, M. D. AU - Venkatesan, N. AU - Finn, R. AU - Yang, G. AU - Rahmeh, M. AU - Untch, M. AU - Rusnak, D. W. AU - Spehar, G. AU - Mullin, R. J. PY - 2006 DA - 2006// TI - Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells JO - Cancer Res VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-05-1182 DO - 10.1158/0008-5472.CAN-05-1182 ID - Konecny2006 ER - TY - JOUR AU - Burris, H. A. AU - Hurwitz, H. I. AU - Dees, E. C. AU - Dowlati, A. AU - Blackwell, K. L. AU - O'Neil, B. AU - Marcom, P. K. AU - Ellis, M. J. AU - Overmoyer, B. AU - Jones, S. F. PY - 2005 DA - 2005// TI - Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.16.584 DO - 10.1200/JCO.2005.16.584 ID - Burris2005 ER - TY - STD TI - Geyer CE, Cameron D, Lindquist D, Chan S, Pienkowski T, Romieu CG, Jagiello-Gruszfeld A, Crown J, Kaufman B, Chan A, et al: A phase III randomized, open-label, international study comparing lapatinib and capecitabine vs. capecitabine in women with refractory advanced or metastatic breast cancer (EGF100151). Presentation at Scientific Special Session, "Lapatinib in Trastuzumab-Resistant Breast Cancer". J Clin Oncol. 2006, 24 (18S): ID - ref63 ER - TY - JOUR AU - Camirand, A. AU - Lu, Y. AU - Pollak, M. PY - 2002 DA - 2002// TI - Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells JO - Med Sci Monit VL - 8 ID - Camirand2002 ER - TY - JOUR AU - DiGiovanna, M. P. AU - Chakraborty, A. PY - 2006 DA - 2006// TI - Combinations of HER2, estrogen receptor (ER) and IGF-I receptor (IGF1R) inhibitors induce apoptosis in breast cancer cells: Dramatic effects of HER2 inhibitors on non-overexpressing cells JO - Proc Am Assoc Cancer Res VL - 47 ID - DiGiovanna2006 ER - TY - JOUR AU - Crul, M. AU - Rosing, H. AU - de Klerk, G. J. AU - Dubbelman, R. AU - Traiser, M. AU - Reichert, S. AU - Knebel, N. G. AU - Schellens, J. H. AU - Beijnen, J. H. AU - ten Bokkel Huinink, W. W. PY - 2002 DA - 2002// TI - Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours JO - Eur J Cancer VL - 38 UR - https://doi.org/10.1016/S0959-8049(02)00127-2 DO - 10.1016/S0959-8049(02)00127-2 ID - Crul2002 ER - TY - JOUR AU - Van Ummersen, L. AU - Binger, K. AU - Volkman, J. AU - Marnocha, R. AU - Tutsch, K. AU - Kolesar, J. AU - Arzoomanian, R. AU - Alberti, D. AU - Wilding, G. PY - 2004 DA - 2004// TI - A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer JO - Clin Cancer Res VL - 10 UR - https://doi.org/10.1158/1078-0432.CCR-03-0406 DO - 10.1158/1078-0432.CCR-03-0406 ID - Van Ummersen2004 ER - TY - JOUR AU - Hidalgo, M. AU - Rowinsky, E. K. PY - 2000 DA - 2000// TI - The rapamycin-sensitive signal transduction pathway as a target for cancer therapy JO - Oncogene VL - 19 UR - https://doi.org/10.1038/sj.onc.1204091 DO - 10.1038/sj.onc.1204091 ID - Hidalgo2000 ER - TY - JOUR AU - Chan, S. AU - Scheulen, M. E. AU - Johnston, S. AU - Mross, K. AU - Cardoso, F. AU - Dittrich, C. AU - Eiermann, W. AU - Hess, D. AU - Morant, R. AU - Semiglazov, V. PY - 2005 DA - 2005// TI - Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.66.130 DO - 10.1200/JCO.2005.66.130 ID - Chan2005 ER - TY - JOUR AU - Fuino, L. AU - Bali, P. AU - Wittmann, S. AU - Donapaty, S. AU - Guo, F. AU - Yamaguchi, H. AU - Wang, H. G. AU - Atadja, P. AU - Bhalla, K. PY - 2003 DA - 2003// TI - Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B JO - Mol Cancer Ther VL - 2 ID - Fuino2003 ER - TY - JOUR AU - Bali, P. AU - Pranpat, M. AU - Swaby, R. AU - Fiskus, W. AU - Yamaguchi, H. AU - Balasis, M. AU - Rocha, K. AU - Wang, H. G. AU - Richon, V. AU - Bhalla, K. PY - 2005 DA - 2005// TI - Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2 JO - Clin Cancer Res VL - 11 UR - https://doi.org/10.1158/1078-0432.CCR-05-0344 DO - 10.1158/1078-0432.CCR-05-0344 ID - Bali2005 ER - TY - JOUR AU - Motoyama, A. B. AU - Hynes, N. E. AU - Lane, H. A. PY - 2002 DA - 2002// TI - The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides JO - Cancer Res VL - 62 ID - Motoyama2002 ER -